4ND-11274-28035
2 vaccinations
1 coded response
8 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 662 / KS
- Registered
- 2021-02-08
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-01-15
Dose 1 — Pfizer-BioNTech
-
2021-02-08
Registered in v-safe
-
2021-02-08
Dose 2 — Pfizer-BioNTech
-
2021-02-09
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Itching · Headache, Fatigue or tiredness · Be unable to workAdult check-in
- 2021-02-09
- 2021-02-10
- 2021-02-11
- 2021-02-12
- 2021-02-13
- 2021-02-17
- 2021-02-22
-
2022-02-08
Survey response — 12 months, dose 2MedDRA: Fatigue, Lymphadenopathy — Feeling: Poor · Be unable to work or attend schoolFree text: swollen lymph nodes & fatigueMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-15 | Pfizer-BioNTech | |
| 2 | 2021-02-08 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-02-09 | priority 2/3 |
Free text
Release 11 — 12 months, dose 2
Symptoms: swollen lymph nodes & fatigue
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Fatigue | · | · | ✓ |
| SD | Lymphadenopathy | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release